Why the study?
Is circulating CCL21 associated with all-cause and cardiovascular mortality in patients with chronic heart failure?
Population
2601 patients with chronic heart failure (1456 from the CORONA trial and 1145 from the GISSI-HF trial)
Design
Cohort
Authors
Loading...
CCL21 may refine mortality risk prediction in chronic HF; hypothesis-generating and requires prospective validation before clinical use.
Is circulating CCL21 associated with all-cause and cardiovascular mortality in patients with chronic heart failure?
Elevated circulating CCL21 levels are independently associated with increased all-cause and cardiovascular mortality in patients with chronic heart failure, modestly improving risk prediction.
Ueland et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: